Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more Dr. Abbey Presented Preliminary Findings of a Diabetic Macular Edema Clinical Trial at the Retina World Congress
Texas Retina Associates’ Ashkan M. Abbey, MD served as an invited faculty member for the Retina World Congress held May 12-15, 2022, in Fort Lauderdale, Florida. This global physician meeting featured presentations
read more
Dr. Kothari and Dr. Abbey Earn “Top 10 Poster Award” at American Society of Retina Specialists 2021 Annual Scientific Meeting
A research poster by Texas Retina Associates physicians Nikisha Kothari, MD, and Ashkan M. Abbey, MD, was awarded “Top 10” honors at the American Society of Retina Specialists (ASRS) 2021 Annual Scientific
read more
New Clinical Trials Enrolling in Plano
At Texas Retina Associates, we remain committed to examining new options that are ethical, based on a solid science platform and provide minimal risks to our patients. Our Plano research team is
read more